Amneal Pharmaceuticals (NYSE:AMRX) Rating Increased to Overweight at Piper Jaffray Companies

Piper Jaffray Companies upgraded shares of Amneal Pharmaceuticals (NYSE:AMRX) from a neutral rating to an overweight rating in a report released on Monday, Benzinga reports. The firm currently has $11.00 price objective on the stock.

AMRX has been the topic of several other research reports. BMO Capital Markets increased their target price on Sun Life Financial from C$58.00 to C$60.00 in a research report on Friday, May 10th. Cantor Fitzgerald restated an overweight rating and set a $130.00 target price (up previously from $116.00) on shares of Zoetis in a research report on Wednesday, June 12th. Barclays restated a hold rating on shares of Bank of Montreal in a research report on Tuesday, June 11th. Raymond James set a C$0.50 target price on Obsidian Energy and gave the stock a market perform rating in a research report on Tuesday, May 21st. Finally, ValuEngine downgraded Whiting USA Trust II from a hold rating to a sell rating in a research report on Tuesday, May 7th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and five have assigned a buy rating to the stock. The company presently has a consensus rating of Hold and a consensus target price of $14.58.

Amneal Pharmaceuticals stock opened at $4.05 on Monday. Amneal Pharmaceuticals has a 12 month low of $4.02 and a 12 month high of $24.48. The company has a current ratio of 2.11, a quick ratio of 1.37 and a debt-to-equity ratio of 3.44. The firm has a 50 day moving average price of $7.21. The stock has a market capitalization of $1.30 billion, a P/E ratio of 4.26, a price-to-earnings-growth ratio of 0.27 and a beta of 1.50.

Amneal Pharmaceuticals (NYSE:AMRX) last posted its earnings results on Thursday, May 9th. The company reported $0.11 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.07). The company had revenue of $446.00 million for the quarter, compared to analysts’ expectations of $438.18 million. Amneal Pharmaceuticals had a positive return on equity of 32.14% and a negative net margin of 3.75%. The business’s quarterly revenue was up 4.9% compared to the same quarter last year. Equities analysts anticipate that Amneal Pharmaceuticals will post 0.91 earnings per share for the current year.

In other Amneal Pharmaceuticals news, SVP Joseph Todisco acquired 15,000 shares of the stock in a transaction that occurred on Monday, May 13th. The shares were bought at an average price of $9.88 per share, for a total transaction of $148,200.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Pradeep Bhadauria acquired 7,000 shares of the stock in a transaction that occurred on Wednesday, May 15th. The stock was acquired at an average price of $8.48 per share, for a total transaction of $59,360.00. The disclosure for this purchase can be found here. Insiders purchased 41,000 shares of company stock worth $387,300 in the last quarter. 26.34% of the stock is currently owned by company insiders.

Hedge funds have recently modified their holdings of the stock. Bessemer Group Inc. bought a new position in Amneal Pharmaceuticals in the fourth quarter valued at $34,000. Quantamental Technologies LLC increased its stake in Amneal Pharmaceuticals by 34.0% in the first quarter. Quantamental Technologies LLC now owns 6,700 shares of the company’s stock valued at $95,000 after acquiring an additional 1,700 shares during the last quarter. Meeder Asset Management Inc. increased its stake in Amneal Pharmaceuticals by 785.6% in the first quarter. Meeder Asset Management Inc. now owns 11,664 shares of the company’s stock valued at $166,000 after acquiring an additional 10,347 shares during the last quarter. First Mercantile Trust Co. increased its stake in Amneal Pharmaceuticals by 40.9% in the first quarter. First Mercantile Trust Co. now owns 11,932 shares of the company’s stock valued at $169,000 after acquiring an additional 3,461 shares during the last quarter. Finally, Amalgamated Bank bought a new position in Amneal Pharmaceuticals in the fourth quarter valued at $174,000. Institutional investors own 36.05% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.

See Also: What is a Reverse Stock Split?

Analyst Recommendations for Amneal Pharmaceuticals (NYSE:AMRX)

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.